The payer's perspective: What is the burden of MS and how should the ă patient's perspective be integrated in health technology assessment ă conducted for taking decisions on access to care and treatment?

Ralf Gold, Mondher Toumi, Bianca Meesen and Emer Fogarty
Additional contact information
Mondher Toumi: Pharmaco-Epidémiologie - Université Bordeaux Segalen - Bordeaux 2 - INSERM - Institut National de la Santé et de la Recherche Médicale

Post-Print from HAL

Abstract: Background: In Europe, there exists considerable variability in access ă to care and treatment for multiple sclerosis (MS). ă Objectives: To improve this situation, we identified key issues payers ă should take into account when making decisions on access to care and ă treatment for MS. We also give an overview of the different dimensions ă determining total MS burden and discuss why it is key to integrate the ă patient's perspective in estimating this burden. ă Results: The total burden of MS relates to three dimensions: clinical, ă humanistic and economic. Although the clinical burden is extensively ă studied, crucial information is still missing about MS pathophysiology, ă how MS-related symptoms will develop during the disease course and which ă patients will progress more rapidly. With regard to the humanistic ă burden, information on patient-reported quality of life systematically ă collected in clinical trials for registration purposes is still scarce. ă Early engagement between pharmaceutical companies, the European ă Medicines Agency and health technology agencies to prospectively ă identify key evidence needs for the regulatory and reimbursement ă processes is required as a first step towards more equal access to care ă and treatment in MS in Europe. Patients' expectations regarding ă treatment outcomes should be better researched and integrated into ă decision-making and patients should be counselled in this process.

Keywords: quality (search for similar items in EconPapers)
Date: 2016-08
References: Add references at CitEc
Citations:

Published in Multiple Sclerosis Journal, 2016, 22 (2), pp.60-70. ⟨10.1177/1352458516650743⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-01482363

DOI: 10.1177/1352458516650743

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().